Rare diseases are no longer a niche topic. They represent one of the greatest untapped potentials in the healthcare system – both medically and economically. Thousands of affected individuals remain undiagnosed for years, receive incorrect diagnoses, or access their therapy far too late. For pharmaceutical companies, this means: The crucial success factor is no longer just the product, but whether patients are found at all. Patient Finding is therefore no longer a nice-to-have, but a central growth driver.
The real problem: Patients are there – but no one sees them
Rare diseases are difficult to recognize, but that's only part of the truth. The reality in the healthcare system paints a different picture: Doctors have little time, rare indications are not top of mind, and diagnostic processes drag on for years. The result is a systemic blind spot problem. Patients exist, move through the system, and yet remain invisible. For pharma, this specifically means: Market potentials remain untapped, therapies reach their target group too late, and growth opportunities are not exploited.
Reach is dead. Relevance is key.
Traditional marketing quickly reaches its limits with rare diseases. Broad campaigns generate visibility, but no decisive impact. Target groups are too small, too specific, and too fragmented. It's no longer about reaching as many as possible, but about finding the right ones. The rules of the game have changed: Precision wins, not reach.
Those who don't find patients lose the market
Patient Finding is not a single process, but an interplay of several levers. It begins with identification: Digital data, communities, and behavioral patterns enable precise targeting of patient groups. This is followed by education: Many rare diseases remain undiagnosed due to a lack of knowledge. Targeted information accelerates diagnoses and shortens the path to therapy. Finally, ongoing support determines long-term success. Without structured support, therapies are discontinued, and patients are lost. Only the interplay of all levels creates real impact and ensures – and ultimately, that is the goal – optimal care.
Not a marketing issue, but a business issue
Patient Finding is often understood as a communication task. In reality, it is a strategic issue that connects Medical, Marketing, Sales, and Patient Care. Companies that integrate these areas achieve measurable effects: faster diagnoses, earlier initiation of therapy, and better utilization of market potential. Through targeted and efficient Patient Finding, we at Medperion Communication can significantly accelerate identification and provide affected individuals with faster access to the necessary treatments.
Isolated measures achieve nothing – systems win
The biggest mistake is to think of Patient Finding in isolation. Individual campaigns fizzle out if they are not embedded in an overarching strategy. Successful approaches combine data, communication, and patient care into an integrated model and apply it along the entire patient journey. Only this creates sustainable market development.
Conclusion: Fail to adapt now, and you'll be left behind.
Rare diseases are fundamentally changing the rules of the game in the pharmaceutical market. It's no longer enough to react to demand. Demand must be actively identified, developed, and supported. Patient finding thus becomes a crucial capability for companies aiming to succeed in this environment. Early investment secures competitive advantages while simultaneously improving patient care.
What needs to be done now
- Systematically analyze and identify patient potential
- Understand diagnostic pathways and patient journeys
- Build targeted and scientifically sound awareness
- Manage communication across relevant touchpoints
- Integrate support services early
